---
title: "ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295792223.md"
description: "Q2 2026 saw stable ZYNLONTA sales and improved net loss, with $18.6M in revenue and $219.1M cash on hand. Regulatory uncertainty persists after FDA concerns on LOTIS-5, but growth is anticipated in 2027 as new data and trials progress.Original document: ADC Therapeutics SA [ADCT] SEC 6-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T11:41:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295792223.md)
  - [en](https://longbridge.com/en/news/295792223.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295792223.md)
generator: "portal-rs"
---

# ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA

Q2 2026 saw stable ZYNLONTA sales and improved net loss, with $18.6M in revenue and $219.1M cash on hand. Regulatory uncertainty persists after FDA concerns on LOTIS-5, but growth is anticipated in 2027 as new data and trials progress.

Original document: ADC Therapeutics SA \[ADCT\] SEC 6-K Current Report — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics Q2 loss narrows; cuts 17% workforce](https://longbridge.com/en/news/295791965.md)
- [ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomas](https://longbridge.com/en/news/295800995.md)
- [Walmart store workers have a new responsibility: correcting AI errors](https://longbridge.com/en/news/296213777.md)
- [ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss](https://longbridge.com/en/news/295792525.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**